ADCT ADC Therapeutics SA
Debt Financing ·
ADC Therapeutics agreed to an $86.6 million private placement and to cut its senior loan to $50.0 million, and its royalty holder gave up a $150 million change-of-control payment. The changes depend on the placement closing, and expected cash at September 30, 2026 was $189.2 million, against $219.1 million at June 30.
The February 18, 2026 amendment sets the change-of-control payment to HCR at $150 million or $200 million and revises a buyout option. HCR received warrants at $3.8130 per share.
ADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share.
ADC Therapeutics is a commercial-stage antibody drug conjugate company headquartered in Lausanne, Switzerland, with operations in New Jersey. Its focus is ZYNLONTA, loncastuximab tesirine-lpyl, a CD19-directed antibody drug conjugate that received accelerated approval from the FDA and conditional approvals from the European Commission, the China National Medical Products Administration and Health Canada for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company is working to move ZYNLONTA into earlier lines of DLBCL through the confirmatory Phase 3 LOTIS-5 trial with rituximab and the Phase 1b LOTIS-7 trial with a bispecific combination, and into indolent lymphomas through investigator-initiated trials. Partnerships extend ZYNLONTA outside the United States. Tanabe Pharma holds a license in Japan, a joint venture with Overland Pharmaceuticals covers China, Singapore and Taiwan, and Swedish Orphan Biovitrum AB holds rights in the other regions excluding the US. Its pipeline includes ADCT-241, an exatecan-based PSMA-targeting antibody drug conjugate for which IND-enabling activities were completed at the end of 2025.
| Product or program | What it is | Stage |
|---|---|---|
| ZYNLONTA (loncastuximab tesirine-lpyl) | CD19-directed antibody drug conjugate for relapsed or refractory DLBCL | accelerated approval (FDA); conditional approvals (EC, NMPA, Health Canada) |
| ADCT-241 | Exatecan-based PSMA-targeting antibody drug conjugate | IND-enabling activities completed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $81.4 million | $70.8 million |
| Research and development | $104.0 million | $109.6 million |
| Net income (loss) | -$142.6 million | -$157.8 million |
| Cash from operations | -$141.2 million | -$123.8 million |
| Cash and equivalents | $261.3 million | $250.9 million |
Our latest story on this, dated Oct 13, 2026: "ADC Therapeutics agrees to $86.6 million PIPE and plans loan cut to $50.0 million". The story links the filing or release it is based on. Read the story.
ADC Therapeutics SA trades under the ticker ADCT on NYSE.
ADC Therapeutics SA is listed on NYSE.
The SEC Central Index Key (CIK) for ADC Therapeutics SA is 1771910. Its filings are on SEC EDGAR.
127,667,695 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-13.
Our directory records ADC Therapeutics SA under Switzerland.
Our directory classifies ADC Therapeutics SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ADC Therapeutics SA is CH0499880968.
aibio.space lists ADC Therapeutics SA among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as V8.
ADC Therapeutics is a commercial-stage antibody drug conjugate company headquartered in Lausanne, Switzerland, with operations in New Jersey. Its focus is ZYNLONTA, loncastuximab tesirine-lpyl, a CD19-directed antibody drug conjugate that received accelerated approval from the FDA and conditional approvals from the European Commission, the China National Medical Products Administration and Health Canada for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
ZYNLONTA (loncastuximab tesirine-lpyl): CD19-directed antibody drug conjugate for relapsed or refractory DLBCL Stage: accelerated approval (FDA); conditional approvals (EC, NMPA, Health Canada).
ADCT-241: Exatecan-based PSMA-targeting antibody drug conjugate Stage: IND-enabling activities completed.
$81.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
ADC Therapeutics SA reported a net loss of $142.6 million for the fiscal year ended Dec 31, 2025, and used $141.2 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio